We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TransEnterix (TRXC) Posts In-Line Loss in Q3, Sales Fall Y/Y
Read MoreHide Full Article
TransEnterix Inc. posted a loss of 9 cents per share in third-quarter 2017, in line with the Zacks Consensus Estimate. The company incurred a loss of 11 cents in the year-ago quarter.
In the reported quarter, total revenues declined to $0.2 million from $1.5 million in the year-ago quarter. The downside can be attributed to deferred service revenues from previous system sales.
Operational Details
In the reported quarter, total operating expenses were $37.8 million compared with $14.0 million in the year-ago quarter.
Research and development expenses declined from $7.0 million in the year-ago quarter to $4.9 million. This was primarily due to the timing of work conducted to prepare FDA submission.
Sales and marketing expenses in the reported quarter rose to approximately $4.5 million from $2.6 million in the prior-year quarter. This was primarily related to headcount growth and other expenses from commercial expansion in Europe.
General and administrative expenses increased to approximately $2.9 million from $2.8 million in the prior-year quarter. This was primarily due to extended support to European commercial investment.
Overall net loss was $38.5 million, wider than $12.9 million in the prior-year quarter.
TransEnterix, Inc. Price, Consensus and EPS Surprise
PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018, up 79.2% from the year-ago quarter’s 24 cents. Gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017, up 216.7% year over year. The company’s revenues in the quarter increased almost 4.1% year over year to $74.1 million.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
TransEnterix (TRXC) Posts In-Line Loss in Q3, Sales Fall Y/Y
TransEnterix Inc. posted a loss of 9 cents per share in third-quarter 2017, in line with the Zacks Consensus Estimate. The company incurred a loss of 11 cents in the year-ago quarter.
In the reported quarter, total revenues declined to $0.2 million from $1.5 million in the year-ago quarter. The downside can be attributed to deferred service revenues from previous system sales.
Operational Details
In the reported quarter, total operating expenses were $37.8 million compared with $14.0 million in the year-ago quarter.
Research and development expenses declined from $7.0 million in the year-ago quarter to $4.9 million. This was primarily due to the timing of work conducted to prepare FDA submission.
Sales and marketing expenses in the reported quarter rose to approximately $4.5 million from $2.6 million in the prior-year quarter. This was primarily related to headcount growth and other expenses from commercial expansion in Europe.
General and administrative expenses increased to approximately $2.9 million from $2.8 million in the prior-year quarter. This was primarily due to extended support to European commercial investment.
Overall net loss was $38.5 million, wider than $12.9 million in the prior-year quarter.
TransEnterix, Inc. Price, Consensus and EPS Surprise
TransEnterix, Inc. Price, Consensus and EPS Surprise | TransEnterix, Inc. Quote
Financial Condition
As of Sep 30, 2017, TransEnterix had $24.5 million in cash and cash equivalents versus $24.2 million as of Dec 31, 2016.
Zacks Rank & Key Picks
Currently, TransEnterix carries a Zacks Rank #3 (Hold).
A few better-ranked medical stocks are PetMed Express, Inc. (PETS - Free Report) , Luminex Corporation and Intuitive Surgical, Inc. (ISRG - Free Report) . While PetMed and Luminex sport a Zacks Rank #1 (Strong Buy), Intuitive Surgical carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed reported earnings per share of 43 cents in the second quarter of fiscal 2018, up 79.2% from the year-ago quarter’s 24 cents. Gross margin expanded 548 bps year over year to 35.2% in the reported quarter.
Luminex reported adjusted earnings per share of 19 cents in the third quarter of 2017, up 216.7% year over year. The company’s revenues in the quarter increased almost 4.1% year over year to $74.1 million.
Intuitive Surgical posted adjusted earnings of $2.77 per share in the third quarter of 2017, up 34.5% on a year-over-year basis. Also, revenues increased 18% year over year to $806.1 million.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>